

SAMPLE REPORT

Client/Sending Facility:
LABCORP OF AMERICA
CMB&P
1912 ALEXANDER DR
RESEARCH TRIANGL, NC 27709
Ph: (919)361-7700
Fax: (919) 361-7798 NCB-13

LCLS Specimen Number: 123456789 Account Number: 123456789
Patient Name: **TEST, TARBR2POS** Ordering Physician: **Dr. 101**
Date of Birth: 01/01/1975 Specimen Type: **BLOOD**
Gender: N Date Collected: 12/10/2013
Patient ID: 12346789 Date Received: 12/11/2013

Test: **BRCA2 Targeted Sequencing** Date Reported: **12/12/2013**

Result: Positive for Familial BRCA2 Variant, Pathogenic

Results Summary:

Gene	Variant Detected	Zygoty	Classification
BRCA2	c.5946delT (p.Ser1982fs)	Heterozygous	Pathogenic

Interpretation:

The known familial BRCA2 variant c.5946delT was detected, and is present in the heterozygous state. The variant detected in BRCA2 has been classified as associated with an increased risk for the Hereditary Breast and Ovarian Cancer Syndrome.

Recommendation:

Genetic counseling is strongly recommended to discuss the clinical implications of this result as well as recommendations for testing other family members. Genetic counselors are available for health care providers to discuss this result further at (800)345-GENE.

Comments:

Only certain BRCA2 regions were sequenced that are believed to harbor the variant(s) of interest associated with Hereditary Breast and Ovarian Cancer Syndrome in this individual's family. Assumptions about the identity of the variant(s) of interest are based on the results of BRCA2 sequence analysis in a blood relative of this individual. The interpretation given here is based on the validity of these assumptions and the results of this limited sequence analysis. Assuming that the variant(s) of interest account(s) for all cases of Hereditary Breast and Ovarian Cancer Syndrome in this individual's family, the fact that the variant(s) of interest was/were not detected indicates that this individual is not at increased risk of Hereditary Breast and Ovarian Cancer Syndrome compared to the general population.

Methods/Limitations:

Selected regions of the coding sequence of BRCA2 are amplified by polymerase chain reaction and each PCR product (amplicon) then sequenced bi-directionally, using Sanger sequencing. Nucleotide and codon number are based on the mRNA isoform NM_000059 for BRCA2 gene.

References:

1. National Comprehensive Cancer Network. Clinical practice guidelines in oncology, genetic/familial high-risk assessment: breast and ovarian. Available at: www.nccn.org. 2010. Accessed 5.29.13.

SAMPLE REPORT

Client/Sending Facility:
LABCORP OF AMERICA
CMB&P
1912 ALEXANDER DR
RESEARCH TRIANGL, NC 27709
Ph: (919)361-7700
Fax: (919) 361-7798 NCB-13

LCLS Specimen Number: 123456789

Patient Name: **TEST, TARBR2POS**

Date of Birth: 01/01/1975

Gender: N

Patient ID: 12346789

Account Number: 123456789

Ordering Physician: **Dr. 101**

Specimen Type: **BLOOD**


Date Collected: 12/10/2013

Date Received: 12/11/2013

2. American Society of Clinical Oncology Policy Statement Update:
Genetic Testing for Cancer Susceptibility. J Clin Oncol. 2003 Jun 15;
21(12):2397-406.

Disclaimer:

Unless stated otherwise in this report, this test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. This test is used for clinical purposes. LabCorp, is regulated under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing.



Alecia Willis, Ph.D., FACMG.

Arundhati Chatterjee, MD
Medical Director

Testing performed by Laboratory Corporation of America Holdings,
1912 Alexander Drive, RTP, NC, 27709-0000 (800) 735-4087